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Abstract
Synthetic cannabinoids are man-made mind-alternating chemicals. Law
enforcement and legislation have attempted to classify many of these synthetic
cannabinoids as schedule I controlled substances, however, they are continuously being
modified by dealers at the retail end of the distribution chain. Addiction and moderate use
of illicit drugs have been identified as major reasons for non-adherence to antiretroviral
therapy among HIV patients. However, there is no data regarding the impact of synthetic
cannabinoid exposure in this population and how this affects their compliancy with
taking antiretroviral therapy. A total of 72 authentic urine specimens were collected
weekly from 13 individuals with HIV from Boom! Health Inc. (Bronx, New York City)
over a 12-week period. We developed and validated an analytical method for the
determination of 24 synthetic cannabinoids and metabolites in these urine samples. Out
of 72 urine samples, 4 tested positive for AB-FUBINACA, UR-144 5-Pentanoic Acid,
UR-144 4-Hydroxypentyl, 5-Fluoro-PB 22 and PB-22 at concentrations that ranged from
1.41-8.93 ng/mL. The urine samples were also screened by immunoassay (EMIT) and
GC-MS. The most common drugs detected were THC, cocaine, opiates, more specifically
methadone and JWH-033. A preliminary LC-MSMS screening for new synthetic
cannabinoids tested mainly positive for THJ-2201, AM2201 and ADB-FUBINACA. For
the future of this research, the impact of synthetic cannabinoids on antiretroviral therapy
discontinuation will be explored comparing urine results with self-report, as well as the
differences in biological matrices (urine and oral fluid) for monitoring synthetic
cannabinoids and classic drugs of abuse.
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1. Introduction
Synthetic Psychoactive Drugs (SPDs) is a catch-all term that includes a
wide range of drugs which have been available in the US for decades, but in recent years,
new types, the so-called novel psychoactive substances (NPS), have emerged in the
market and their use has rapidly grown problematic among particular subpopulations.
NPS are a heterogeneous group of newly synthesized compounds that mimic classic drug
effects (cocaine, amphetamines, cannabis, MDMA, heroin), but are pharmacologically
more potent and with unknown short and long-term effects. These drugs are easy to
obtain (smart shops, internet) and many of them are “legal” (not scheduled substances).
Among NPS, synthetic cannabinoids (SC) (known colloquially as “K2”) are the most
prevalent group.
SC are man-made mind-altering chemicals created to mimic cannabis. They are
normally sprayed on plant material and are falsely advertised in convenience stores as
herbal incenses and air fresheners. They may also be sold as liquids that are smoked in
vaporizers. These drugs have no medical benefit which has lead to classifying many of
them as a schedule I controlled substance; however, NPS chemical structures are
continuously modified by dealers at the retail end of the distribution chain in response to
legislation and law enforcement efforts to make them less available (NIDA, 2015). For
users, it has the additional benefit of making these novel compounds and their
metabolites not easily detected by routine screening and confirmation tools in the
laboratory. Many laboratories are using mass spectrometric screening methods as an
alternate source to immunoassay methods (Heikman et al., 2016). In New York City,
NPS, in particular SC, have become especially popular with some homeless people and
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those who are subject to drug testing (like people living in supervised residences for
mental health or substance use problems, active duty armed service members, and people
on parole and probation).
Although SC act on the same cell receptors (CB1 and CB2) as delta-9tetrahydrocannabinol (THC), they are actually much more potent than THC and have
effects that are unpredictable and life threatening (Behonick et al., 2014). Current
evidence suggests that SC pose a greater risk to user health than cannabis (Fantegrossi et
al., 2014). It is also noteworthy that SC users have typically experimented with a wider
variety of drugs than non-SC users and that they co-ingest SC along with other
substances that may be problematic, but not thoroughly explored (Bonar et al., 2014).
A wide range of symptoms have been associated with SC use and have been
reported in the media, including psychotic episodes, paranoia, increased anxiety and
hallucinations, increased heart rate, agitation, vomiting, seizures, uncontrollable body
movements, lack of emotional attachment, sweating, loss of control, red eyes, dry mouth,
and many others. Symptoms that some K2 users exhibit or experience may be the
outcome of several factors. For example, the chemical content of the substance may
change over time as dealers attempt to avoid the law, and these changes to the
composition of the bags offered for retail sale may produce dramatically different effects
among users (NIDA, 2015). Still more variation in the symptoms exhibited by NPS users
may be the product of interaction effects with other drugs that they may use, like alcohol,
cocaine, amphetamines, heroin or any number of pharmaceutical products. Most of the
K2 exposures are based on self-report, but the actual toxicological information about the
specific compounds involved in these cases, the concentrations detected in biological
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specimens, how these concentrations correlate with the clinical outcome, and their
combination with other drugs is scarce.
Addiction and moderate use of illicit drugs have been identified as major reasons
for non-adherence to antiretroviral therapy among HIV patients. However, there is no
information about the impact of K2 exposure in this population and how this affects their
adherence to antiretroviral therapy.
The objective of this study was to monitor SC and drugs of abuse exposure in
HIV-infected individuals following antiretroviral therapy. We developed and validated an
analytical method for the determination of 11 SC (A-796260, AB-FUBINACA, ABPINACA, 5-Fluoro PB-22, JWH-018, JWH-073, XLR-11, UR-144, PB-22, APINACA
(AKB-48), and MAM2201) and 13 metabolites (AB-PINACA 5-Pentanoic acid, JWH018 5-Pentanoic acid, JWH-073 4-Butanoic acid, JWH-250 4-Hydroxypentyl, AM2201
4-Hydroxypentyl, JWH-019 5-Hydroxyhexyl, JWH-122 4-Hydroxypentyl, UR-144 5Pentanoic acid, XLR-11 4-Hydroxypentyl, UR-144 4-Hydroxypentyl, MAM2201 4Hydroxypentyl, APINACA (AKB-48) 5-Hydroxypentyl, JWH-210 4-Hydroxypentyl) in
urine samples, and we screened these samples for new SC and classic drugs of abuse.
2. Methods
2.1 Reagents and supplies
All standards (A-796260, AB-PINACA 5-Pentanoic acid, AB-FUBINACA, ABPINACA, JWH-018 5-Pentanoic acid, JWH-073 4-Butanoic acid, JWH-250 4Hydroxypentyl, AM2201 4-Hydroxypentyl, 5-Fluoro PB-22, JWH-019 5-Hydroxyhexyl,
JWH-122 4-Hydroxypentyl, UR-144 5-Pentanoic acid, XLR-11 4-Hydroxypentyl, UR144

4-Hydroxypentyl,

MAM2201

4-Hydroxypentyl,

APINACA

(AKB-48)

5-

4

Hydroxypentyl, JWH-210 4-Hydroxypentyl, JWH-018, JWH-073, XLR-11, UR-144, PB22, APINACA (AKB-48), and MAM2201) and internal standards (JWH-250 4Hydroxypentyl-D5, AM2201 4-Hydroxypentyl-D5, and JWH-210 4-Hydroxypentyl-D5)
were purchased from Cerilliant (Round Rock, TX). Ammonium acetate, acetic acid,
acetonitrile, ethyl acetate, methanol were obtained from Pharmco-Apper (Brookfield,
CT), and formic acid from Fisher Scientific (Fair Lawn, NJ). Water was purified by an
ELGA Purelab Ultra Analytic purifier (Siemens Water Tech, Lowell, MA). All solvents
were HPLC or better. Abalone beta-glucuronidase containing 100,000 units/mL was
purchased from Campbell Science (Rockford, IL). 1mL Isolute SLE+ cartridges were
utilized for preparing samples from Biotage, Inc. (Charlotte, NC). A Restrep 24-port SPE
manifold (Restek Inc., Bellefonte, PA) was used for specimen extraction. A Kinetex C18
column (100 x 2.1 mm) combined with a guard column with the same chemistry (10 x 2.1
mm) was purchased from Phenomenex Inc. (Torrance, CA) and was used for analytical
chromatography. During method development a Kinetex F5 column (100 x 2.1 mm)
combined with a guard column (10 x 2.1 mm), as well as Novum SLE+ cartridges
utilized for preparing samples were explored and acquired from Phenomenex Inc.
2.2 Sample collection and storage
A total of 72 authentic urine specimens were collected from 13 individuals from
Boom! Health Inc. (Bronx, New York City) weekly, over a 12-week period. The
participants provided written informed consent to participate in this study. The study was
approved by The City University of New York IRB. Urine specimens were collected by
the participants in FisherbrandTM 4 oz. polypropylene specimen containers (Fisher
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Scientifc, Waltham, MA), aliquoted in 2 mL polypropylene cryotubes (Fisher Scientific)
and stored in the freezer at -20° C until analysis.
2.3 Synthetic Cannabinoids Confirmatory Method
2.3.1. Instrumentation
A Shimadzu (Columbia, MD) ultra high performance liquid chromatography
tandem mass spectrometer (UHPLC-MS/MS) LCMS-8030, equipped with a Shimadzu
Nexera X2 LC-30AD ultra high performance liquid chromatograph (UHPLC) coupled to
an electrospray and atmospheric-pressure chemical ionization (ESI/APCI) dual probe
ionization source and a triple quadrupole mass spectrometer was employed.
2.3.2. Calibrators, quality control and internal standards
Stock solutions of each synthetic cannabinoid (11 parent compounds and 13
metabolites) were created in methanol or acetontrile at concentrations of 10 µg/mL.
Dilutions of the stock solutions created working solutions containing all 24 SC in
methanol at concentrations 5, 50, 100, and 400 ng/mL. Blank urine from healthy
volunteers was then fortified with the working solutions to create calibrators and quality
control samples at concentrations 1, 5, 10, 15, 20, 40, 50 and 100 ng/mL (see Table 1).
Table 1: Calibrators and quality controls sample preparation. Volume of working
solutions employed to fortify blank urine samples to yield calibrators and quality controls
at concentrations 1 to 100 ng/mL.
Calibrators/
Working Solutions
Quality Controls
5 ng/mL
50 ng/mL
100 ng/mL
400 ng/mL
1 ng/mL
40 uL
5 ng/mL
20 uL
10 ng/mL
20 uL
QC 15 ng/mL
30 uL
20 ng/mL
40 uL
40 ng/mL
80 uL
QC 50 ng/mL
25 uL
100 ng/mL
50 uL
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Internal Standard
Mix

-

-

50 uL

-

Each deuterated internal standard stock solution was created in methanol at a
concentration of 10 µg/mL. A working solution containing all three of the internal
standards was prepared at 0.1 µg/mL in methanol. All stock solutions and working
solutions were stored at -20° in amber vials.
2.3.3 Specimen extraction
Sample extraction followed the protocol described by Scheidweiler and Huestis
(Scheidweiler & Huestis, 2014). For preparation, 200 µL of blank urine was placed into
polyproplyene microcentrifuge tubes, followed by 50 µL of the internal standard mix.
This was diluted with 0.3 mL of 400 mM ammonium acetate buffer, pH 4.0, prior to the
addition of 40 µL of glucuronidase solution (100,000 units glucuronidase activity/mL).
The polyproplyene microcentrifuge tubes were then capped and incubated at 55°C for 2
hours. Five hundred µL of acetonitrile was added and then the samples were centrifuged
at 6,500 rpm at 4°C for 5 minutes. The supernatant was then transferred onto the Biotage
SLE columns and driven onto the column phase with slight pressure. After keeping
equilibrium at constant pressure for 5 minutes, analytes were eluted with 6 mL of ethyl
acetate into polyproplyene microcentrifuge tubes. Pressure was applied for 5 minutes
until elution was complete. All samples were completely dried at 45°C under nitrogen in
a Biotage TurboVap. Samples were reconstituted in 150 µL mobile phase A:B, 85:15
(v/v), vortexed for 15 seconds prior to centrifugation at 4°C at 6,500 rpm for 5 minutes
and then transferred to autosampler vials containing 300 µL inserts. Mobile phase (A)
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consisted of 0. 1% formic acid in UHP water and mobile phase (B) consisted of 0. 1%
formic acid in acetonitrile.
2.3.4. LC-MS/MS
Chromatographic separation was performed on a Kinetex C18 column with an
attached guard column containing the same packing material. A 12-minute positive
ionization method with a 20 µL injection volume was performed each time samples or
standards were injected. Gradient elution was performed with two mobile phases (A, 0.
1% formic acid in UHP water, and B, 0. 1% formic acid in acetonitrile), a flow rate of 0.4
mL/min and initial column oven temperature at 35°C. The initial conditions of the
gradient were 15% B, held for 2.5 minutes, increased to 50% by 2.5 minutes, and then
increased again to 60% by 5.75 minutes. It was then increased to 95% B by 6.75 minutes
and held at 95% until 9.0 minutes. It was then returned to 15% B by 9.5 minutes and held
at 15% until 12 minutes was reached.
The mass spectrometric data was collected in scheduled multiple reactionmonitoring (MRM) mode. The MRM windows were 1 to 3.5 minutes, 3.5 to 4.75
minutes, 4.75 to 6.5 minutes, and 6.5 minutes to 9 minutes. Respectively, in the first
MRM window compounds: A-796260, and AB-PINACA 5-Pentanoic acid were
monitored. In the second MRM window: AB-FUBINACA, AB-PINACA, JWH-018 5Pentanoic acid, JWH-073 4-Butanoic acid, JWH-250 4-Hydroxypentyl, AM2201 4Hydroxypentyl, JWH-250 4-Hydroxypentyl-D5, and AM2201 4-Hydroxypentyl-D5 were
monitored. In the third MRM window, the compounds: 5-Fluoro PB-22, JWH-019 5Hydroxyhexyl, JWH-122 4-Hydroxypentyl, UR-144 5-Pentanoic acid, XLR-11 4Hydroxypentyl, UR-144 4-Hydroxypentyl, MAM2201 4-Hydroxypentyl, JWH-210 4-
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Hydroxypentyl-D5,

APINACA

(AKB-48)

5-Hydroxypentyl,

and

JWH-210

4-

Hydroxypentyl were monitored. In the last MRM window, the compounds: JWH-018,
JWH-073, XLR-11, UR-144, PB-22, APINACA (AKB-48), and MAM2201 were
monitored. These analytes were optimized by individually injecting 2 µL at a
concentration of 1 µg/mL. Quantifier and qualifier ion transitions were monitored for
each analyte and internal standard (see Table 2).
Table 2: Liquid chromatography-tandem mass spectrometry parameters for synthetic
cannabinoids and metabolites in human urine, the underlined product (m/z) is the
quantifier ion
Analyte
Peak Precursor
Product (m/z)
Q1 (V)
CE
Q3 (V) Retention
#
(m/z)
Time
(min)
JWH-018
22
341.8
126.95, 154.95 -22, -22 -48, -27 -26, -30
7.392
JWH-073
20
327.8
127, 154.9
-21, -21 -50, -24 -27, -11
7.144
XLR-11
21
330
55.1, 125
-15, -15 -46, -26 -22, -27
7.202
UR-144
23
311.9
54.95, 124.90 -13, -13 -43, -24 -22, -27
7.610
A-796260
2
355.1
114.1, 125
-17, -17 -32, -24 -23, -26
3.102
AB3
369
109.05, 253.05 -10, -10 -45, -27 -22, -18
3.731
FUBINACA
5-Fluoro PB15
377
143.85, 232.10 -25, -25 -42, -16 -15, -17
5.522
22
PB-22
18
358.8
143.95, 214
-16, -16 -37, -17 -15, -10
6.927
AB-PINACA
6
331
144.95, 215.10 -15, -15 -42, -26 -15, -25
4.192
APINACA
24
366.1
135.1, 93.15
-10, -10 -24, -54 -14, -18
7.951
(AKB-48)
MAM2201
19
373.8
141.05, 168.95 -16, -16 -45, -29 -29, -18
7.090
JWH-018 57
372
126.9, 154.85 -10, -10 -49, -24 -13, -17
4.351
Pentanoic acid
JWH-073 45
358
126.95, 154.95 -10, -10 -49, -23 -27,-16
4.111
Butanoic acid
JWH-019 510
372
127, 154.95
-10, -10 -49, -25 -26, -30
4.984
Hydroxyhexyl
JWH-250 44
351.80
91.15, 121
-22, -22 -55, -25 -19, -26
4.006
Hydroxypentyl
JWH-122 412
372
140.95, 169.05 -10, -10 -47, -24 -29, -18
5.060
Hydroxypentyl
JWH 210 416
386.1
154.9, 183
-10, -10 -40, -26 -29, -20
5.664
Hydroxypentyl
AM2201 48
376
127.05, 155
-16, -16 -49, -27 -27, -30
4.445
Hydroxypentyl

9

UR-144 5Pentanoic acid
XLR-11 4Hydroxypentyl
AB-PINACA
5-Pentanoic
acid
APINACA
(AKB-48) 5Hydroxypentyl
UR-144 4Hydroxypentyl
MAM2201 4Hydroxypentyl
JWH-250 4Hydroxypentyl
-D5
AM2201 4Hydroxypentyl
-D5
JWH-210 4Hydroxypentyl
-D5
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342

55.1, 125

-15, -15 -45, -24 -23, -28

4.987

13

346.1

55.1, 125

-15, -15 -42, -25 -22, -26

5.156

1

261.1

217.1, 227.1

-16, -16 -31, -32 -10, -24

2.689

17

382.1

79, 135.15

-18, -18 -55, -27 -16, -29

5.822

14

328.1

55, 125.05

-30, -30 -44, -22 -22, -26

5.271

9

390

140.9, 168.95

-17, -17 -50, -27 -30, -12

4.932

4

357

91.1, 121.1

-10, -10 -55, -25 -10, -26

4.006

8

381.1

126.95, 154.95

-10, -10 -53, -29 -28, -30

4.445

16

390.9

154.9, 183

-13, -13 -44, -29 -11, -19

5.664

2.3.5. Method validation
Method validation was completed for the following categories: linearity, limit of
detection, limit of quantification, accuracy and imprecision, extraction efficiency, matrix
effect, and process efficiency by procedures described by the Scientific Working Group
for Forensic Toxicology (SWGTOX, 2013).
Linearity, limit of detection, limit of quantification
Linearity was completed over five days using least squares regression with 1/x2
weighing factor. If the coefficient of determination (r2) was greater than 0.99 and
residuals were < 20%, satisfactory linearity was accomplished. Limit of detection (LOD)
and limit of quantification (LOQ) were determined by injecting fortified samples with
decreasing analyte concentrations. The LOD had a signal to noise ratio that was greater
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than 3, had the presence of all product ions, correct ion ratio, and a retention time within
±0.2 minutes of the calibrator retention time. The LOQ was satisfied when the lowest
concentration had imprecision less then ±20% and an accuracy of 80-120%.
Accuracy and imprecision
Intra-day and inter-day accuracy, and imprecision were determined from three
replicates at two different quality control concentrations (15 and 50 ng/mL) within the
dynamic range of the calibration curve over five days. Intra-day and inter-day accuracy
was determined by how close the result averages were to that specific quality control
concentration. The values were expected to be within 80-120%. Intra-day and inter-day
imprecision was calculated by the coefficient of variation and was expected to be less
than 20%.
Extraction efficiency, matrix effect and process efficiency
Three sets of samples were prepared, and all samples were prepared at a
concentration of 15 ng/mL. Set one was prepared by creating three neat samples.
Standards and internal standards were evaporated and reconstituted with mobile phase.
Set two was prepared by taking ten different blank urine samples, running them through
the SLE procedure and then fortifying them with the standards and internal standards
directly before evaporation. Set three was prepared by taking five different blank urines,
fortified them with the corresponding standard and internal standard solutions, and
running them through the normal procedure for authentic samples. In order to determine
the extraction efficiency, set two and set three were compared. In order to determine if
there were any matrix effects set one and set two were compared and lastly, in order to
determine the process efficiency set one and set three were compared.
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Identification Criteria
In order to confirm if a synthetic cannabinoid was present using the LC-MSMS
several factors must be considered. Firstly, the retention time of the synthetic cannabinoid
must be within ±0.2 minutes of the calibrator retention time. Secondly, both the quantifier
and qualifier product ion must be present and lastly, the ion ratio between the qualifier
and quantifier product ion must be within ±20% of the calibrators’ ion ratio average.
2.4 Screening methods
Urine samples were submitted to 3 screening methods. An immunoassay method
to detect classic drugs of abuse, a general unknown screening method by GC-MS and a
screening method for new emerging SC by LC-MSMS.
The urine samples were screened for tetrahydrocannabinol (THC), amphetamines,
barbiturates, benzodiazepines, cocaine, and opiates by the enzyme multiplied
immunoassay technique Viva-Jr (EMIT) from Siemens Healthineers Global (Erlangen,
Germany). To accomplish this, 500 µL of each authentic urine sample was placed into
small plastic cups. The information for each sample was entered under ‘order samples’
and the drugs that were to be tested for were checked. The samples were then loaded onto
the outer rotor in their assigned positions.
Urine samples were also submitted to a general unknown screening by gas
chromatography-electron impact-mass spectrometry-QP2010 (GC-MS) from Shimadzu
(Columbia, MD). From each day authentic samples were run for SC confirmation by LCMSMS, 100 uL of each urine sample, 100 uL of one of the 50 ng/mL quality control and
100 uL of the 100 ng/mL calibrator extracts were taken out of the LC-MSMS vials and
were placed in separate polyproplyene microcentrifuge tubes, evaporated in the
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TurboVap under nitrogen at 50°C for 25 minutes and then reconstituted in 100 µL of
methanol. They then were placed into new vials and subjected to the GC-MS method that
scanned for the presence of any analyte over a 20-minute period monitoring 50-600 m/z.
The gradient used for this method started at 85°C and was held for one minute, increased
15°C until 145°C was reached and then increased 35°C until the final temperature of
285°C was achieved. This temperature was then held out for 11 minutes. Data analysis
was performed using the SWGDRUG library.
The extracted urine samples were also re-injected in the LC-MSMS by a
screening method to detect additional SC, for which reference standards were not
available. The chromatographic separation was the same as that for the confirmatory LCMSMS separation and the MS mode was set to scan between 100 to 600 m/z. Data
analysis was performed extracting the m/z of the pseudomolecular ion (molecular weight
+ 1) of 18 newly discovered SC: NM2201, MMB-CHMICA, MDMB-FUBINACA,
JWH-081, FUB-AK848 AM2201, ADB-FUBINACA, AB-CHMINACA, 5F-ABPINACA, THJ-2201, JWH-122, JWH-250, JWH-019, 5F-AMB, JWH-073, JWH-018,
5F-MDMB-PINACA, and FUB-AMB.
3. Results
3.1 Chromatography
Chromatographic or/and mass resolution between all analytes was possible (see
Figure 1); retention times did not drift more than ±0.2 minutes.
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Figure 1: Total ion chromatogram of synthetic cannabinoids, metabolites, and internal
standards in urine at a concentration of 100 ng/mL
3.2 Method Validation
Linearity, limit of detection, limit of quantification
All SC had a limit of detection and limit of quantification of 1 ng/mL. The
linearity of the SC and metabolites was from 1-100 ng/mL (see Table 3).
Table 3:
Synthetic cannabinoids and metabolites in human urine by liquid
chromatography-tandem mass spectrometry calibration results (N=5), the limit of
detection for all compounds was 1 ng/mL, and the linear range for all compounds was 1100 ng/mL
Analyte
Internal Standard
Y-Intercept
Slope mean
R2 mean
mean (SD)
(SD)
(SD)
0.001285625
0.088997
0.99020452
JWH-018
JWH-210 4(0.001)
(0.03)
(0.009)
Hydroxypentyl-D5
0.000190703
0.1551028
0.99065512
JWH-073
JWH-210 4(0.0002)
(0.03)
(0.01)
Hydroxypentyl-D5
0.001077198
0.1515736
0.99369148
XLR-11
JWH-210 4(0.0008)
(0.03)
(0.006)
Hydroxypentyl-D5
0.00101602
0.05249972
0.99511818
UR-144
JWH-210 4(0.0004)
(0.01)
(0.007)
Hydroxypentyl-D5
0.002378198
0.49611
0.9929449
A-796260
JWH-250 4(0.002)
(0.08)
(0.005)
Hydroxypentyl-D5
0.000537662
0.2525566
0.9946481
AB-FUBINACA
JWH-250 4(0.0006)
(0.01)
(0.003)
Hydroxypentyl-D5
0.011676242
0.9580168
0.99620564
5-Fluoro PB-22
AM2201 4(0.01)
(0.2)
(0.009)
Hydroxypentyl-D5
0.001611057
0.731283
0.99053004
PB-22
JWH-210 4-
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AB-PINACA
APINACA (AKB-48)
MAM2201
JWH-018 5-Pentanoic
acid
JWH-073 4-Butanoic
acid
JWH-019 5Hydroxyhexyl
JWH-250 4Hydroxypentyl
JWH-122 4Hydroxypentyl
JWH 210 4Hydroxypentyl
AM2201 4Hydroxypentyl
UR-144 5-Pentanoic acid
XLR-11 4Hydroxypentyl
AB-PINACA 5Pentanoic acid
APINACA (AKB-48) 5Hydroxypentyl
UR-144 4-Hydroxypentyl
MAM2201 4Hydroxypentyl

Hydroxypentyl-D5
JWH-250 4Hydroxypentyl-D5
JWH-210 4Hydroxypentyl-D5
JWH-210 4Hydroxypentyl-D5
JWH-250 4Hydroxypentyl-D5
JWH-250 4Hydroxypentyl-D5
AM2201 4Hydroxypentyl-D5
JWH-250 4Hydroxypentyl-D5
AM2201 4Hydroxypentyl-D5
JWH-210 4Hydroxypentyl-D5
AM2201 4Hydroxypentyl-D5
AM2201 4Hydroxypentyl-D5
AM2201 4Hydroxypentyl-D5
JWH-250 4Hydroxypentyl-D5

(0.002)
0.00195856
(0.001)
0.001086573
(0.0006)
0.002376595
(0.001)
0.000785989
(0.0009)
0.000792057
(0.0005)
0.001531423
(0.002)
0.001989142
(0.002)
0.002209517
(0.002)
0.00318269
(0.004)
0.002349407
(0.002)
0.002796446
(0.001)
0.005536802
(0.003)
0.001051535
(0.0007)

(0.4)
0.594795
(0.05)
0.283854
(0.3)
0.2201186
(0.04)
0.363893
(0.04)
0.7494644
(0.07)
0.7399262
(0.07)
0.7494644
(0.07)
0.76232868
(0.05)
1.456368
(0.07)
0.8856404
(0.07)
0.9145226
(0.1)
1.194048
(0.1)
0.1576032
(0.04)

(0.008)
0.99410202
(0.004)
0.99645138
(0.002)
0.9912271
(0.005)
0.99353618
(0.004)
0.9977849
(0.004)
0.99373754
(0.005)
0.9977849
(0.001)
0.9910738
(0.009)
0.99844944
(0.0008)
0.9971077
(0.003)
0.99712128
(0.001)
0.99729258
(0.002)
0.99268886
(0.005)

JWH-210 4Hydroxypentyl-D5
AM2201 4Hydroxypentyl-D5
AM2201 4Hydroxypentyl-D5

0.008628364

1.6892476
(0.8)
1.529212
(0.2)
0.6073746
(0.05)

0.99490436
(0.005)
0.9957305
(0.002)
0.99489582
(0.001)

0.003869283
(0.004)
0.001184963
(0.001)

Accuracy and imprecision
The intra-day imprecision and accuracy for the synthetic cannabinoid metabolites
was 1.0-14.6% and 83.3-105.5% respectively. For inter-day, the results for imprecision
and accuracy was as follows: 3.3-10.5% and 84.9-103.8%. In the case of the synthetic
cannabinoid parent compounds, the intra-day imprecision and accuracy was 5.4-91.1%
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and 48.3-122.1% respectively. For inter-day, the results for imprecision and accuracy was
as follows: 5.3-85.4% and 73.9-102.7% (see Table 4).
Table 4: Analytical accuracy and imprecision data for synthetic cannabinoids and
metabolites at quality controls 15 and 50 ng/mL in human urine by liquid
chromatography-tandem mass spectrometry
Analyte
Imprecision (mean)
Accuracy (mean)
Inter-day
Intra-day
Inter-day
Intra-day
(N=15)
(N=3)
(N=15)
(N=3)
15
50
15
50
15
50
15
50
JWH-018
30.6
41.6
32.1
62.9
94.8
74.5
103.7
66.9
JWH-073
15.3
27.3
13.0
43.8
97.6
86.4
107.2
93.1
XLR-11
11.5
17.8
7.6
26.2
94.3
84.5
98.0
89.3
UR-144
44.2
53.3
43.4
77.6
96.9
73.9
122.1
70.9
A-796260
5.3
8.4
0.7
11.2
97.1
100.6
93.1
100.1
AB6.8
6.6
5.4
7.0
96.9
102.6
90.3
100.9
FUBINACA
5-Fluoro PB-22
26.3
9.8
26.3
9.8
95.6
102.0
96.2
92.0
PB-22
12.2
18.5
15.6
31.5
102.2
89.6
115.7
94.6
AB-PINACA
8.7
7.6
11.0
15.5
97.2
102.7
86.6
99.8
APINACA
71.7
85.4
50.4
91.1
89.7
79.1
119.0
48.3
(AKB-48)
MAM2201
12.8
24.3
10.5
14.4
95.5
84.9
101.8
80.4
JWH-018 58.5
7.7
4.7
1.4
96.1
101.4
83.3
92.5
Pentanoic acid
JWH-073 47.3
6.3
4.3
2.5
97.5
102.0
87.3
94.2
Butanoic acid
JWH-019 56.8
7.1
3.9
4.8
98.1
102.1
89.0
95.3
Hydroxyhexyl
JWH-250 45.5
5.1
2.8
2.0
98.9
101.2
93.4
97.7
Hydroxypentyl
JWH-122 49.8
8.2
6.6
8.2
98.6
103.8
92.7
101.7
Hydroxypentyl
JWH 210 43.3
3.9
1.5
1.0
98.8
100.6
95.0
96.3
Hydroxypentyl
AM2201 44.5
5.5
2.4
3.0
99.4
102.0
94.5
100.6
Hydroxypentyl
UR-144 55.2
7.5
5.7
8.1
100.7
101.6
94.7
93.5
Pentanoic acid
XLR-11 44.8
7.4
4.9
9.9
100.3
100.2
96.3
95.5
Hydroxypentyl
AB-PINACA
5.6
8.0
4.3
4.2
99.1
98.2
94.8
87.4
5-Pentanoic
acid
APINACA
7.3
9.1
3.3
2.2
99.9
101.8
93.0
105.5
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(AKB-48) 5Hydroxypentyl
UR-144 4Hydroxypentyl
MAM2201 4Hydroxypentyl

6.3

8.7

5.6

14.6

99.2

98.3

92.6

92.6

6.7

10.5

6.6

3.5

98.4

103.5

88.8

95.9

Extraction efficiency, matrix effect, and process efficiency
For synthetic cannabinoid metabolites, the extraction efficiencies were from 83.2107.4%, matrix effects from -22 to -41.7%, and process efficiencies from 60.7-104.9%.
For synthetic cannabinoid parent compounds, the extraction efficiencies were from 4298.4%, matrix effects from -11.9 to -65.3%, and process efficiencies were from 23.186.7% (see Table 5).
Table 5: Mean extraction efficiencies, matrix efficiencies and process efficiencies for
synthetic cannabinoids and metabolites at quality control 15 ng/mL extracted from urine
by supported-liquid extraction
Analyte
Extraction
Matrix Efficiency
Process Efficiency
Efficiency
JWH-018
59.9
-57.1
25.7
JWH-073
53.5
-56.8
23.1
XLR-11
47.3
-51.1
23.2
UR-144
42.0
-26.7
30.8
A-796260
90.7
-46.6
48.5
AB-FUBINACA
93.9
-42.3
54.2
5-Fluoro PB-22
77.6
-27.4
56.4
PB-22
91.2
-65.3
31.6
AB-PINACA
98.4
-11.9
86.7
APINACA (AKB-48)
89.7
-13.0
78.1
MAM2201
83.9
-57.5
35.7
JWH-018 5-Pentanoic
95.6
-22.7
73.9
acid
JWH-073 4-Butanoic
94.8
-8.9
86.4
acid
JWH-019 5100.7
-25.7
74.9
Hydroxyhexyl
JWH-250 495.0
-36.1
60.8
Hydroxypentyl
JWH-122 4100.0
-36.2
63.8
Hydroxypentyl
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JWH 210 4Hydroxypentyl
AM2201 4Hydroxypentyl
UR-144 5-Pentanoic
acid
XLR-11 4Hydroxypentyl
AB-PINACA 5Pentanoic acid
APINACA (AKB-48)
5-Hydroxypentyl
UR-144 4Hydroxypentyl
MAM2201 4Hydroxypentyl

107.4

-40.9

63.5

97.0

-22.2

75.5

102.5

-37.1

64.5

101.7

-32.3

68.8

83.2

26.1

104.9

105.7

-28.9

75.1

104.0

-41.7

60.7

90.7

-23.6

69.3

3.3 Authentic urine samples analysis
This method was applied to the measurement of SC and metabolites from the 72
authentic urine samples. From these authentic urine samples, 4 tested positive and were
collected from 3 different participants. The SC and metabolites detected were ABFUBINACA (3.02 ng/mL), UR-144 Pentanoic Acid (2.97-8.93 ng/mL), UR-144 4Hydroxypentyl (1.71 ng/mL), 5-Fluoro PB-22 (1.41 ng/mL), and PB-22 (1.41 ng/mL).
See Table 6. Figure 2 shows a chromatogram of an authentic urine sample positive for
UR-144 5-Pentanoic Acid.
Table 6: Authentic urine results positive for synthetic cannabinoids and metabolites
Sample ID
Collection Date
Synthetic Cannabinoid (+)
Concentration
(ng/mL)
CSG7410451
15-Jun-2016
AB-FUBINACA
3.02
CSG7410451
23-Jun-2016
UR-144 5-Pentanoic Acid
8.93
UR-144 4-Hydroxypentyl
1.71
GLG8010451
13-Jul-2016
UR-144 5-Pentanoic Acid
2.97
3260122164
31-Aug-2016
5-Fluoro-PB 22
1.41
PB-22
1.41

18

Figure 2: Individual GLG8010451 showing positive result (2.97 ng/mL) for UR-144 5Pentanoic Acid
3.4 Screening methods
From the EMIT screening, 25 urine samples tested positive for opiates; 36 tested
positive for cocaine; 23 tested positive for benzodiazepines, and 40 tested positive for
THC. As for the other two drugs on the panel, barbiturates and amphetamines, all 72
cases came back negative (see Table 7).
Table 7: EMIT screening results (N=72)
Drug
Opiate
Cocaine
Benzodiazepine
Barbiturate
Amphetamine
THC

Number of Cases Tested Positive
25
36
23
0
0
40

After analyzing the general unknown GC-MS screening, 45 urine samples
screened positive for methadone; 44 urine samples screened positive for JWH-033; 1
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urine sample screened positive for cyclobarbital; 1 urine sample screened positive for
venlafaxine; 4 urine samples screened positive for gabapentin (see Figure 3,4); 2 urine
samples screened positive for buphedrone metabolite; 2 urine samples screened positive
for cocaine; 1 urine sample screened positive for methylephedrine; 4 urine samples
screened positive for mirtazephine, and 1 urine sample tested positive for
diphenhydramine (see Table 8).
Table 8: GC-MS screening results (N=72)
Drug
Methadone
JWH-033
Cyclobarbital
Venlafaxine
Gabapentin
Buphedrone Metabolite
Cocaine
Methylephedrine
Mirtazephine
Diphenhydramine

Number of Cases Screened Positive
45
44
1
1
4
2
2
1
4
1

Figure 3: Chromatogram of individual GLG8010451 from GCMS screening
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Figure 4: Library search of peak 1 from chromatogram of individual GLG8010451
(Figure 3) showing positive GCMS screening result for gabapentin
After attempting to detect additional new SC with the LC-MSMS screening, 60
urine samples screened positive for NM2201; 13 urine samples screened positive for
MMB-CHMICA; 6 urine samples screened positive for MDMB-FUBINACA and JWH081; 60 urine samples screened positive for AM2201; 65 urine samples screened positive
for ADB-FUBINACA; 46 urine samples screened positive for AB-CHMINACA; 4 urine
samples screened positive for 5F-AB-PINACA; 56 urine samples screened positive for
JWH-250; 1 urine samples screened positive for 5F-AMB; 43 urine samples screened
positive for JWH-018; 33 urine samples screened positive for 5F-MDMB-PINACA; and
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11 urine samples screened positive for FUB-AMB. All 72 urine samples screened
positive for THJ-2201 (see Figure 5), while no urine samples screened positive for FUBAK848, JWH-122, JWH-019, and JWH-073 (see Table 9).
Table 9: LC-MSMS screening results (N=72)
Synthetic Cannabinoid
Molecular Weight
NM2201
376
MMB-CHMICA
371
MDMB-FUBINACA
372
JWH-081
372
FUB-AK848
404
AM2201
360
ADB-FUBINACA
383
AB-CHMINACA
357
5F-AB-PINACA
349
THJ-2201
361
JWH-122
356
JWH-250
336
JWH-019
356
5F-AMB
364
JWH-073
328
JWH-018
342
5F-MDMB-PINACA
378
FUB-AMB
384

Number of Cases Screened Positive
60
13
6
6
0
69
65
46
4
72
0
56
0
1
0
43
33
11

Figure 5: Extracted chromatogram of individual F74722015SW from LC-MSMS
screening showing positive result for THJ-2201
4. Discussion
There have been a number of methods published in order to determine SC and
their metabolites in urine, (Scheildweiler et al., 2015; Ozturk, et al., 2015; Bertol et al.,
2015; Castaneto et al., 2105; Jang et al., 2015; Hutter et al., 2012), and there have been
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numerous methods for the determination of drugs of abuse and their non-adherence to
antiretroviral therapy (Moore et al., 2012; Hosseini et al., 2106; Cohn et al., 2011).
However, there is limited evidence on how the exposure to these new NPS called SC
correlates with HIV-infected patients and their adherence to antiretroviral therapy.
By developing and validating an analytical method for the determination of 11 SC
(A-796260, AB-FUBINACA, AB-PINACA, 5-Fluoro PB-22, JWH-018, JWH-073,
XLR-11, UR-144, PB-22, APINACA (AKB-48), and MAM2201) and 13 metabolites
(AB-PINACA 5-Pentanoic acid, JWH-018 5-Pentanoic acid, JWH-073 4-Butanoic acid,
JWH-250 4-Hydroxypentyl, AM2201 4-Hydroxypentyl, JWH-019 5-Hydroxyhexyl,
JWH-122 4-Hydroxypentyl, UR-144 5-Pentanoic acid, XLR-11 4-Hydroxypentyl, UR144

4-Hydroxypentyl,

MAM2201

4-Hydroxypentyl,

APINACA

(AKB-48)

5-

Hydroxypentyl, JWH-210 4-Hydroxypentyl) in urine samples, an initial assessment can
be conducted in order to see how well urine as a biological matrix for detecting SC would
be. The parent drugs of SC were included in order to see what other information about
recent intake could be observed, even though their metabolites are more predominantly
detected in urine (Scheidweiler et al., 2014). However, due to the lack of standards of
these SC, it was important to run a screening test with new SC that are currently
emerging to see which of these are most popular amongst this population. As more
standards become available, they easily can be introduced into the confirmatory method
so a more accurate representation of what SC being taken can be accounted for. A
screening test for other drugs of abuse was also conducted in order to see which other
drugs were being taken solely or concurrently with the SC.
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Since Boom! Health Inc. is an organization that helps individuals and
communities impacted by drug use, especially those with HIV, and since these
individuals have admitted to drug use, positive results were expected. Three different
individuals tested positive for the SC being monitored; one tested positive for different
SC two weeks in a row. Due to the small amount of SC actually being monitored it is
unclear whether or not the other individuals present in this study took SC that were not
being monitored. Likewise, making screening for emerging SC important. It was rather
alarming that 45 and 44 of the samples collected were screened positive for methadone
and the synthetic cannabinoid JWH-033 respectively. In addition, many of these
individuals screened positive for opiates, benzodiazepines, THC, and or cocaine.
Urine proved to be a decent biological matrix to test for synthetic cannabinoids
achieving linearity and excellent accuracy and imprecision for all metabolites. The intraday imprecision and accuracy for the synthetic cannabinoid metabolites were 1.0-14.6%
and 83.3-105.5% respectively. For inter-day, the results for imprecision and accuracy
were as follows: 3.3-10.5% and 84.9-103.8%. Equally as impressive, extraction
efficiencies ranged from 83.2-107.4%, matrix effects from -22 to -41.7%, and process
efficiencies from 60.7-104.9%. Our research method was adapted from research done by
Scheidweiler and Huetis (2014). They reported analytical recovery from 83.3 to 118.3%
of expected concentrations for intra-day and inter-day analytical recoveries and intra-day
and inter-day imprecision from 0.8–9.1 and 4.3–13.5%, respectively. They also reported
mean extraction efficiencies of 43.7–109.3% (n = 10) and mean matrix effects of −73.1 to
51.7%. Our results show slightly better accuracy, as well as less matrix effects and higher
extraction efficiencies.
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After conducting our validation, the imprecision was above the permitted range of
20% for the synthetic cannabinoids: JWH-018, UR-144 and APINACA (AKB-48) for our
research, and because of that these compounds can’t be quantified with this method. So,
unfortunately, even though individual 3260122164 had a confirmed positive result of
1.44 ng/mL of UR-144 present in their urine, it may not be considered a positive result.
For the future of this research, the impact of SC on antiretroviral therapy
discontinuation will be explored as well as the differences in biological matrices (urine
and oral fluid) for monitoring SC and classic drugs of abuse.
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